4213 studies found for:    Japan
Show Display Options
Rank Status Study
1 Recruiting A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation
Condition: Chronic Constipation
Interventions: Drug: ASP0456;   Drug: Placebo
2 Recruiting Phase III Study of GSK1278863 in Japanese Non-dialysis and Peritoneal Dialysis Subjects With Renal Anemia
Condition: Anaemia
Interventions: Drug: 1 to 4 mg tablets of GSK1278863;   Drug: 6 mg GSK1278863 tablet;   Drug: Epoetin beta pegol
3 Recruiting Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)
Condition: All Patients Treated With the Product
Intervention:
4 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
5 Recruiting Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
6 Not yet recruiting A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Dulaglutide;   Drug: Placebo
7 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
8 Recruiting Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: ART-123;   Drug: Placebo
9 Recruiting Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: SOF;   Drug: RBV
10 Recruiting Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/UMEC/VI;   Drug: FF/VI;   Drug: UMEC;   Drug: Placebo;   Drug: Albuterol/salbutamol
11 Recruiting Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Celecoxib;   Biological: Tanezumab 5 mg;   Biological: Tanezumab 10 mg;   Drug: Placebo for celecoxib;   Biological: Placebo for tanezumab
12 Active, not recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
Conditions: Chronic Hepatitis C Virus;   Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: Sofosbuvir;   Drug: Ribavirin
13 Recruiting A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Condition: Rheumatoid Arthritis
Interventions: Drug: ABT-494;   Drug: Placebo
14 Active, not recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
Conditions: Chronic Hepatitis C Virus;   Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: Ombitasvir/paritaprevir/ritonavir
15 Recruiting A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
Condition: Rheumatoid Arthritis
Interventions: Drug: ABT-494;   Drug: Methotrexate;   Drug: ABT-494 matching placebo;   Drug: Methotrexate matching placebo
16 Recruiting A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: ABT-494;   Drug: Methotrexate;   Drug: ABT-494 matching placebo;   Drug: Methotrexate matching placebo
17 Recruiting Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: 25 mg Omecamtiv Mecarbil;   Drug: Placebo;   Drug: 37.5 mg Omecamtiv Mecarbil;   Drug: 50 mg Omecamtiv Mecarbil
18 Recruiting BI 655066 Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: BI 655066;   Drug: placebo to ustekinumab;   Drug: ustekinumab;   Drug: placebo to BI 655066
19 Recruiting Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
Condition: Erosive Esophagitis
Interventions: Drug: Vonoprazan;   Drug: Lansoprazole
20 Not yet recruiting Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
Condition: Osteoarthritis
Intervention: Drug: Investigational Medical Product (IMP) administered in parent study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years